Integra Lifesciences (NASDAQ: IART) SVP uses 937 shares for tax withholding
Jeffrey Mosebrook, SVP and Principal Accounting Officer of Integra Lifesciences (NASDAQ: IART), reported a tax-related share disposition where 937 common shares were delivered at $17.89 each to satisfy tax obligations. Following this transaction, Mr. Mosebrook directly holds 34,516 shares of the company's common stock. This "F" coded transaction indicates shares were used for tax liability payment rather than an open-market sale.
Integra LifeSciences (IART) EVP awarded 11,180 RSUs in new equity grant
Integra LifeSciences Holdings Corp's EVP, Robert T. Davis Jr., has been granted 11,180 restricted stock units (RSUs) as part of his equity compensation. These RSUs, which represent a contingent right to receive one share of common stock each, will vest in full on the second anniversary of the grant date, provided Davis remains with the company. Following this award, his direct holdings of RSUs total 54,530.
Integra LifeSciences (IART) grants EVP 5,590 RSUs vesting over 3 years
Integra LifeSciences (IART) has granted Harvinder Singh, EVP & President, SS, 5,590 restricted stock units (RSUs) under its 2003 Equity Incentive Plan. These RSUs will vest in three equal annual installments over three years, contingent on his continued service. Following this grant, Mr. Singh's direct holdings of RSUs total 68,883.
Integra Lifesciences Holdings Corp (IART) Stock Forecast, Price Targets and Analysts Predictions
This article provides a stock forecast, price targets, and analyst predictions for Integra Lifesciences Holdings Corp (IART). It details the current market capitalization, enterprise value, PE Ratio, and PB Ratio, along with its GuruFocus score. The content primarily serves as an overview for investors interested in IART's financial data and analyst coverage.
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences Holdings Corporation has appointed Topaz Kirlew as its corporate vice president and chief regulatory officer. Kirlew will be responsible for leading the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives. She has extensive experience in the healthcare and medical technology industries, having served as interim regulatory leader for Integra and held roles at various other organizations.
Integra LifeSciences Names Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences Holdings Corp. has appointed Topaz Kirlew as corporate vice president and chief regulatory officer. Kirlew will oversee the company's global regulatory strategy, submissions, compliance, and transformation initiatives, bringing over 35 years of experience in healthcare and medical technology regulatory affairs. Her appointment aims to strengthen Integra's compliance and quality systems during a period of increasingly complex global regulatory requirements.
Integra LifeSciences taps interim regulatory chief for global role
Integra LifeSciences (Nasdaq: IART) has appointed Topaz Kirlew as corporate vice president and chief regulatory officer, where she will lead global regulatory affairs and strategy. Kirlew previously served as interim regulatory leader, bringing over 35 years of experience in healthcare and medical technology across various regulatory, quality, operations, clinical, and laboratory roles. Her appointment aims to strengthen the company’s regulatory capabilities and reinforce compliance.
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences has appointed Topaz Kirlew, DBA, MBA, as its corporate vice president and chief regulatory officer. Kirlew will be responsible for leading the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives. She has extensive experience in the healthcare and medical technology industries, having served as interim regulatory leader for Integra and held roles at various other organizations.
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences has appointed Topaz Kirlew as its corporate vice president and chief regulatory officer. Kirlew will lead the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives worldwide. She brings over 35 years of experience in healthcare and medical technology and has been instrumental in building the company's regulatory capabilities since joining in 2021.
Integra LifeSciences Holdings (IART) Could Be 31% Undervalued Following Leadership Changes
Integra LifeSciences Holdings (IART) has restructured its commercial leadership, appointing new executives to enhance execution and customer focus. Despite a weak five-year shareholder return, the company shows strong recent momentum, trading at $18.74 with a fair value estimated at $27.00, suggesting it is 30.6% undervalued. This valuation is based on expected operational improvements, margin recovery, and long-term earnings growth, though regulatory and pricing risks remain.
Integra LifeSciences Holdings stock hits 52-week high at $18.30
Integra LifeSciences Holdings (IART) stock has reached a new 52-week high of $18.30, more than doubling its 52-week low. This surge is attributed to robust performance, including impressive Q1 2026 financial results that surpassed analyst expectations and an upgrade to a Buy rating by Argus. InvestingPro analysis suggests the stock remains undervalued despite its recent gains, indicating strong potential for future growth.
Zacks.com featured highlights TPG Mortgage Investment Trust, Silvercorp and Integra LifeSciences
The article highlights TPG Mortgage Investment Trust (MITT), Silvercorp Metals Inc. (SVM), and Integra LifeSciences Holdings Corp. (IART) as strong investment opportunities based on recent broker rating upgrades. These upgrades signal potential upside driven by improved analyst outlooks, although investors are advised to consider these recommendations alongside other fundamental and valuation factors. The companies show strong projected earnings growth for their respective fiscal years.
Zacks.com featured highlights TPG Mortgage Investment Trust, Silvercorp and Integra LifeSciences
Zacks.com highlights TPG Mortgage Investment Trust (MITT), Silvercorp Metals Inc. (SVM), and Integra LifeSciences Holdings Corp. (IART) as strong buy candidates due to recent broker rating upgrades. These upgrades signal potential upside, driven by factors like strong corporate earnings, AI-driven optimism, and a supportive economy. The article emphasizes that broker recommendations, when combined with other fundamental analysis, can help investors identify stocks with significant growth potential.
Integra Lifesciences Holdings Corp (IART) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Integra Lifesciences Holdings Corp (IART), highlighting its current price momentum score of 8.88 and noting that its stock is trading between resistance at $19.35 and support at $16.02, suggesting suitability for range-bound swing trading. The analysis includes detailed technical indicators such as MACD, RSI, KDJ, and moving averages, which collectively suggest a "Buy" signal based on the MA5 to MA200.
Integra Lifesciences Holdings Corporation Announces Executive Changes
Integra LifeSciences Holdings Corporation announced several leadership appointments within its commercial organization. Robert T. Davis Jr. has been appointed Executive Vice President, Tissue Reconstruction and Distributed Technologies, while Christopher Kilburn-Peterson was promoted to Corporate Vice President and President for the Tissue Reconstruction division. Harvinder Singh succeeded Mike McBreen as Executive Vice President and President of the Specialty Surgery division.
Integra LifeSciences reshuffles commercial leadership in medtech push
Integra LifeSciences (Nasdaq: IART) announced significant commercial leadership changes to enhance customer focus and accelerate growth. Robert T. Davis Jr. was appointed EVP, Tissue Reconstruction and Distributed Technologies, while Christopher Kilburn-Peterson was promoted to Corporate VP and President of Tissue Reconstruction. Harvinder Singh became EVP and President of Specialty Surgery, and international leaders will now report directly to Chief Commercial Officer Mike McBreen to strengthen commercial execution and deepen customer engagement.
Integra LifeSciences Stock - Sunday background on risks and outlook
This article provides a Sunday background look at Integra LifeSciences (IART) stock, focusing on its business profile, key risks, and future outlook. It highlights past quality control issues, current valuation, and earnings expectations, noting that investors are watching remediation efforts and margin recovery. The company, a medical technology specialist, derives revenue from various medical devices and instruments, with its stock trading on Nasdaq.
Argus upgrades Integra LifeSciences stock rating on turnaround
Argus has upgraded Integra LifeSciences Holdings (NASDAQ:IART) to Buy from Hold, setting a price target of $25.00 due to expected earnings turnaround driven by executive changes and resolution of production issues. The medical technology company exceeded Q1 EPS expectations and raised guidance, with analysts forecasting profitability this year. InvestingPro analysis suggests the stock remains undervalued despite a 38% year-to-date increase.
Argus upgrades Integra LifeSciences stock rating on turnaround By Investing.com
Argus has upgraded Integra LifeSciences Holdings (NASDAQ:IART) stock rating to Buy from Hold, setting a price target of $25.00. The upgrade is attributed to executive changes, resolved production issues, and an expected earnings turnaround, along with consistent growth. Integra LifeSciences reported strong first-quarter 2026 financial results, exceeding analyst expectations for both EPS and revenue, further supporting the optimistic outlook.
Integra Lifesciences Holdings Corp (IART) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a detailed revenue breakdown for Integra Lifesciences Holdings Corp (IART) by business segment and geographical region. It shows that Neurosurgery accounts for over 50% of its revenue, and the United States contributes the largest share regionally. The data is current as of April 6, 2026, and includes details for multiple fiscal years.
Integra Lifesciences Holdings Corp (IART) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Integra Lifesciences Holdings Corp (IART), listing its major institutional holders and their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, hedge funds, and individual investors. Additionally, the report provides historical institutional shareholding data and details recent shareholder activity, alongside related ETF holdings.
Integra Lifesciences Holdings Corp (IART) Earnings Forecast: Future EPS & Revenue Growth Estimates
Integra Lifesciences Holdings Corp (IART) has an earnings forecast score of 5.80, ranking 185 out of 203 in its industry. Analysts have set an average price target of $13.00, with a range from $10.00 to $25.00, and a general "Hold" rating. The company's expected revenue for the next quarter is $418.76M, and its EPS for the upcoming quarter is projected at $0.48.
Integra Lifesciences Holdings Corp (IART) Institutional Confidence
Integra Lifesciences Holdings Corp (IART) has an institutional shareholding score of 10.00, ranking 1st in the Healthcare Equipment & Supplies industry. Institutional holdings increased by 10.94% quarter-over-quarter, with 106.43% of shares held by institutions. ETHSX is the largest institutional shareholder with 2.00M shares, representing 4.15% of outstanding shares.
Integra LifeSciences Holdings Corporation (IART) Hits Fresh High: Is There Still Room to Run?
Integra LifeSciences Holdings Corporation (IART) has recently reached a new 52-week high, with its stock up 23.7% in the past month and 40.6% year-to-date. The company has consistently beaten earnings estimates, reporting EPS of $0.54 against a consensus of $0.41 in its last report. Despite its recent surge, the article explores valuation metrics and the Zacks Rank to assess future growth potential, noting its strong Zacks Rank of #2 (Buy) and favorable style scores.
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
Integra LifeSciences Holdings Corporation announced that Bob Davis, executive vice president and president of Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00 PM ET. A live webcast of the presentation will be available on the company's investor relations website. Integra LifeSciences (Nasdaq: IART) is a medical technology company focused on neurosurgery and tissue reconstruction.
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
Integra LifeSciences Holdings Corporation (Nasdaq: IART) announced that Bob Davis, executive vice president and president of Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00 PM ET. A live webcast of the presentation will be available on the company's investor relations website. The company is a global medical technology leader focusing on neurosurgery and tissue reconstruction.
Live webcast of Integra Truist MedTech talk set for June 16
Integra LifeSciences (Nasdaq: IART) announced that Bob Davis, executive vice president and president Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00pm ET. A live webcast of the presentation will be available on the company’s investor relations website. This presentation is part of Integra LifeSciences' ongoing investor outreach efforts.
Integra LifeSciences stock hits 52-week high at 17.84 USD
Integra LifeSciences Holdings (IART) stock has reached a 52-week high at $17.84, driven by impressive year-to-date gains of 36.39% and strong first-quarter 2026 financial results that surpassed analyst expectations. The company reported adjusted earnings per share of $0.54 and revenue of $392 million, reflecting robust growth and market confidence. Despite the high, InvestingPro analysis suggests the stock may still be undervalued, indicating potential for further upside.
Integra (IART) EVP awarded RSUs and stock options in new grant
Michael J. McBreen, EVP & Chief Commercial Officer at Integra LifeSciences Holdings Corp (IART), was granted 31,909 restricted stock units and a non-qualified stock option for 60,372 shares with an exercise price of $15.67. Both awards vest in three equal annual installments, contingent on his continued service. Following the RSU grant, McBreen directly holds 124,017 shares of common stock.
Integra (IART) CEO receives new RSU and stock option grants
Integra LifeSciences Holdings Corp (IART) CEO Stuart Essig was granted 365,297 Restricted Stock Units (RSUs) and 705,468 non-qualified stock options on June 1, 2026. These awards, part of his employment agreement and at the discretion of the Compensation Committee, will vest over 25 months starting May 1, 2026. The stock options have an exercise price of $15.6700 per share.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Integra LifeSciences (IART) Investors of Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm's Attorneys
Hagens Berman is reminding investors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) about a pending securities fraud class action lawsuit. The lawsuit alleges that Integra made misleading statements and failed to disclose Good Manufacturing Practices violations at its Boston Facility, leading to a global recall of products and a significant drop in stock prices. The firm encourages investors who suffered substantial losses to contact their attorneys for legal consultation.
CFO Lea Knight to speak June 3 at Jefferies healthcare forum
Integra LifeSciences announced that its Chief Financial Officer, Lea Knight, will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the company's investor relations website. This presentation is part of Integra LifeSciences' ongoing investor relations efforts, which have recently included positive reactions from leadership changes and strong Q1 2026 financial results.
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CFO Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website. The company is a global medical technology leader focused on neurosurgery and tissue reconstruction.
Integra LifeSciences Hits New 52-Week High at $16.62
Integra LifeSciences Holdings Corp. reached a new 52-week high of $16.62 on May 28, 2026, despite a significant 46.3% decline in its stock performance over the past year. The company, which operates in the Pharmaceuticals & Biotechnology sector, has a market capitalization of $746 million and a P/E ratio of 6.00. Investors will be watching to see how these financial metrics influence its future trajectory.
Integra LifeSciences Hits Day High with 8.36% Surge in Stock Price
Integra LifeSciences Holdings Corp. experienced an 8.36% surge in its stock price, reaching an intraday high of USD 16.62. The company has shown significant short-term growth, with a 53.26% increase over the past month and 32.53% year-to-date, outperforming the S&P 500. Despite these gains, Integra LifeSciences has faced challenges in long-term profitability, including a decline in operating profit over the last five years and underperformance compared to the market over the past year.
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra LifeSciences Holdings Corporation announced that its Chief Financial Officer, Lea Knight, will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 4:20 PM PT. A live webcast of the presentation will be available on the company's investor relations website. Integra LifeSciences is a global medical technology company focused on neurosurgery and tissue reconstruction.
IART Upgraded by Citigroup -- Price Target Raised to $16.00
Citigroup has upgraded Integra Lifesciences (IART) from Sell to Neutral, raising its price target to $16.00. While GuruFocus indicates the stock is undervalued by 30.8% with a GF Value of $23.74, its GF Score of 64/100 reveals mixed performance, with strengths in profitability but challenges in growth and financial strength. Investors are advised to exercise caution despite the upgrade.
Integra LifeSciences stock hits 52-week high at $16.49
Integra LifeSciences Holdings (IART) stock has reached a 52-week high of $16.49, marking an 85% surge from its 52-week low and a 22.3% year-to-date return. This follows strong first-quarter 2026 financial results where the company surpassed analyst expectations for both EPS and revenue. Despite an RSI suggesting the stock is overbought, InvestingPro analysis indicates it may still be undervalued relative to its Fair Value.
Integra LifeSciences Names Stuart Essig CEO in Leadership Return, Adds New Commercial Chief
Integra LifeSciences has appointed its board chairman, Stuart M. Essig, as president and CEO, effective May 1, 2026. Essig previously served as CEO from 1997 to 2012 and his return emphasizes strengthening execution, operational consistency, and commercial focus. Simultaneously, Michael McBreen has been named Chief Commercial Officer, a new role to centralize global commercial operations and align market strategy with revenue performance.
Former Integra CEO Stuart Essig returns, board skips CEO search
Integra LifeSciences has appointed former CEO Stuart Essig as its new President and CEO, effective May 1, 2026. He will also continue to serve as chairman. The company explicitly stated that Essig's appointment is permanent and they will not be initiating a CEO search. Additionally, Michael McBreen has been named chief commercial officer to lead the global commercial organization.
Integra LifeSciences Announces Leadership Transition
Integra LifeSciences Holdings Corporation announced that Stuart M. Essig has been appointed president and chief executive officer, effective May 1, 2026. He will also continue to serve as chairman of the Board, replacing Mojdeh Poul. Additionally, Michael McBreen has been appointed chief commercial officer, a newly created role to drive commercial performance and focus on customer and market-facing priorities.
The Top 5 Analyst Questions From Integra LifeSciences’s Q1 Earnings Call
Integra LifeSciences reported a Q1 performance that exceeded expectations, driven by strong demand for tissue reconstruction products, improved supply, and operational initiatives. The company's revenue and adjusted EPS surpassed analyst estimates, leading to a positive market reaction. Analysts questioned the CEO transition, the status of their Compliance Master Plan, portfolio optimization, revenue guidance, and market share recapture efforts for product relaunches.
Paradigm Capital holds 4.01M shares of Integra LifeSciences (IART)
Paradigm Capital Management, Inc. has disclosed a 5.16% stake in Integra LifeSciences Holdings Corp (IART), holding 4,012,698 shares of Common Stock as of March 31, 2026. This ownership, reported via a Schedule 13G SEC filing, indicates a passive investment where Paradigm Capital exercises sole voting and dispositive power on behalf of its advisory clients. The filing highlights that these holdings exceed the 5% reporting threshold for passive institutional investors.
Integra LifeSciences Announces Leadership Transition
Integra LifeSciences has announced a leadership transition, appointing Stuart M. Essig as president and chief executive officer, effective May 1, 2026. Essig, who previously served as CEO from 1997 to 2012 and has been chairman since 2012, replaces Mojdeh Poul. Additionally, Michael McBreen has been named chief commercial officer in a newly created role to enhance commercial strategy and accelerate execution.
Integra LifeSciences (IART) director receives 17,700 RSU grant
Integra LifeSciences director Shaundra Clay was granted 17,700 restricted stock units (RSUs) on May 7, 2026, as part of the company's equity incentive plan. These RSUs, each representing one share of IART common stock, will vest fully on the one-year anniversary of the grant date. Clay has opted to defer the receipt of these shares until after her service on the Board ends.
Integra (IART) director receives 24,338-share stock awards
Integra Lifesciences Holdings Corp (IART) director Barbara B. Hill was granted 24,338 shares of common stock on May 7, 2026, as equity compensation. This included two awards of 17,700 shares and 6,638 shares, both at $0.00 per share. Following these transactions, Hill directly owns 151,191 shares, with an additional 36,350 shares held indirectly through a trust.
Renee Wonlai Lo awarded 17,700 RSUs at Integra LifeSciences (IART)
Integra LifeSciences director Renee Wonlai Lo was granted 17,700 Restricted Stock Units (RSUs) as equity compensation. These RSUs, which represent a contingent right to receive one share of IART common stock each, will vest in full on May 7, 2027, the one-year anniversary of the grant date. This award increases her reported RSU holdings to 17,700 units, aiming to align her interests with shareholder value.
Integra LifeSciences (IART) director awarded 17,700 deferred RSUs
Integra LifeSciences director Christian S. Schade was granted 17,700 restricted stock units (RSUs) on May 7, 2026, which will vest entirely one year from the grant date. Schade has elected to defer the receipt of these shares until after his service on the Board of Directors concludes. This award was part of the company's Fifth Amended and Restated 2003 Equity Incentive Plan, with a transaction price of $0.00, indicating a compensation grant rather than a purchase.
Integra LifeSciences (IART) director Jeffrey Graves receives 17,700 RSU award
Integra LifeSciences Holdings Corp. director Jeffrey A. Graves was granted 17,700 Restricted Stock Units (RSUs) on May 7, 2026, under the company's 2003 Equity Incentive Plan. Each RSU represents a contingent right to one share of IART common stock, and the award vests in full on the one-year anniversary of the grant date. Following this transaction, Graves directly holds 17,700 RSUs.
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra LifeSciences Holdings Corporation announced that CFO Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 4:20 pm PT. A live webcast of the presentation will be available on the company's investor relations website. The company is a global medical technology leader focusing on neurosurgery and tissue reconstruction.
